Calidi Biotherapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering for gross proceeds of $6 million.
The offering includes common stock units and pre-funded warrant units at specific prices per unit.
The company expressed satisfaction in pricing the transaction despite challenging market conditions.
Transaction Details
Offering comprised of common stock units and pre-funded warrant units at defined prices per unit.
Underwriters
Ladenburg Thalmann & Co. Inc. is the sole book-running manager, with Laidlaw & Company (U.K.) Ltd. as a co-manager.
Closing Date
Offering expected to close on or about August 21, 2025, subject to customary closing conditions.
- Calidi Biotherapeutics aims to use the proceeds to advance its pioneering development of targeted therapies.
- The involvement of existing shareholders, new investors, and management indicates confidence in the company's growth potential.
Calidi Biotherapeutics' successful pricing of the public offering reflects investor confidence in the company's innovative approach to delivering genetic medicines.